Other candidates such as EGR1, RUNX2, STAT1, TRAP2, IRF1 and USF1 have been experimentally validated as drug targets, metastasis promoter or tumor growth enhancers, see19–24. This evidence concerns the gene RUNX2 and neoplasm.